74T-12273-85133
2 vaccinations
1 coded response
6 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 684 / NE
- Registered
- 2021-01-10
- Relationship
- Self
Timeline
-
2020-12-18
Dose 1 — Pfizer-BioNTech
-
2021-01-08
Dose 2 — Pfizer-BioNTech
-
2021-01-10
Registered in v-safe
-
2021-01-10
Survey response — days 1–6 daily, dose 2MedDRA: Sensitive skin — Feeling: Poor · Site: Pain · Chills, Headache, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Skin sensitivityMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-10
Report sent to call center — days 1–6 daily, dose 2Be unable to do your normal daily activities1 call case(s)
- 2021-01-13
- 2021-01-14
- 2021-01-31
- 2021-02-05
- 2021-02-06
- 2021-02-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-18 | Pfizer-BioNTech | |
| 2 | 2021-01-08 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-01-10 | Unsuccessful |
Free text
Release 1 — days 1–6 daily, dose 2
Systemic reaction (other): Skin sensitivity
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Sensitive skin | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release